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Abstract
Apolipoprotein E externally added to neuroblastoma cells in culture stimulates [35S]sulfate incorporation on cell and
extracellular matrix glycosaminoglycans (sGAG). This stimulation is mainly observed for ApoE4 compared to ApoE3. The
increase in sulfation is not due to increased synthesis as there is no corresponding increase in the [3H]glucosamine
incorporation. Since the presence of ApoE is a risk factor for Alzheimer’s disease (AD) and the presence of sGAG could
facilitate the assembly of the main components, L-amyloid and tau proteins, of the aberrant structures found in AD, the
present study indicates a possible relation between those factors. ß 2001 Elsevier Science B.V. All rights reserved.
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Alzheimer’s disease is characterized neuropatho-
logically by the presence of two aberrant structures
amyloid containing plaques or senile plaques (SP)
and neuro¢brillary tangles (NFT) [1]. NFT are ag-
gregates of ¢brillar polymers, the paired helical ¢la-
ments (PHF), and the main component of these ¢l-
aments is the microtubule associated protein tau [2].
It has been indicated that in both aberrant struc-
tures, SP and NFT, found in AD, there are present
other molecules like sulfated glycosaminoglycans
(sGAG) [3,4], and in vitro experiments it has been
observed that sGAG could promote the polymeriza-
tion of the main components of SP and NFT, L
amyloid and tau protein [5^7].
On the other hand, it was indicated that apolipo-
protein E (apoE) allele L4 is a risk factor in sporadic
AD [8]. Di¡erent functional di¡erences have been
shown for the expression of L4 compared with the
most common allele L3 in processes like neurite ex-
tension [9]. Additionally, di¡erences has been postu-
lated, in vitro, in the interaction of ApoE3 or ApoE4
with tau or L amyloid proteins [10,11].
It has been reported that ApoE stimulates the pro-
duction of sGAG, like heparin, in endothelial cells
[12] but no stimulation was observed in other cell
types like macrophages or ¢broblasts (which pre-
dominantly produce chondroitin and dermatan sul-
fate PGs) by exogenous ApoE, and perlecan PG in
smooth muscle cells [13]. However, recently [14] in-
creased PG production in ApoE-transfected macro-
phages and ¢broblasts has been shown.
In this work we have studied if ApoE could also
stimulate the production of sGAG in a neuroblasto-
ma cell line and if, in the case of positive results, if
ApoE3 and ApoE4 made it in a di¡erent extension,
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since it may facilitate the explanation of the possible
di¡erent role of ApoE alleles in AD.
Our results indicate that ApoE stimulates the pro-
duction of sGAG in a more e⁄cient way than
ApoE3.
To determine the e¡ect of ApoE on the production
of sGAG, neuroblastoma cells were incubated with
lipidated-ApoE (dimyristoyl-phosphatidylcholine-re-
constituted) [15] for 16 h, with a yield of recovered
protein higher than 80% in all cases. A dose depen-
Fig. 1. ApoE stimulates the production of sGAG. Con£uent monolayers of neuroblastoma cells in 100 mm plates were incubated
with the indicated amounts of the recombinant isoform ApoE3 or ApoE4 for 16 h (left panel) or with 10 Wg for the indicated times
(right panel) in growth medium (DMEM and 15% fetal calf serum) containing [35S]sulfate (250 WCi/plate) at 37‡C, 95% CO2 and 5%
O2. Cell-associated [35S]sulfate-sGAG was determined extracting the cells by a 5 min incubation in 20 mM NH4OH in 0.1% Triton
X-100 at room temperature and counting an aliquot by scintillation. Values represent the mean þ S.D. of three independent experi-
ments.
Fig. 2. ApoE increases the sulfation of extracellular GAGs. Con£uent monolayers of neuroblastoma cells in 100 mm plates were incu-
bated with the indicated amounts of the recombinant isoform ApoE3 or ApoE4 for 16 h (left panel) or with 10 Wg for the indicated
times (right panel) in growth medium (DMEM and 15% fetal calf serum) containing [35S]sulfate (250 WCi/plate) at 37‡C, 95% CO2
and 5% O2. The amount of extracellular matrix [35S]sulfate-GAG was determined after extracting by incubation with 6 M guanidine
hydrochloride for 4 h at room temperature. Values represent the mean þ S.D. of three independent experiments.
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dent experiment in which 35SO4 incorporation in
sGAG was tested against increasing amounts of
ApoE was done. 35SO4 incorporation was measured
in the cell-associated sGAG fraction, by removing
the cells with NH4OH 20 mM/Triton X-100 0.1%
for 5 min, and in the extracellular matrix by extrac-
tion with 6 M guanidine hydrochloride for 4 h as
described before [16]. Testing two forms of ApoE,
one containing ApoE3 [17] (Calbiochem) and the
other one containing ApoE4 (Calbiochem) extended
the study. Fig. 1A shows the incorporation of 35SO4
into the cell-associated sGAG, upon incubation of
neuroblastoma cells for 16 h in the presence of in-
creasing amounts of ApoE3 or ApoE4: Fig. 1B
shows the kinetics of 35SO4 incorporation at di¡erent
times after addition of ApoE3 or ApoE4.
A similar analysis to that previously indicated was
done for the extracellular matrix fraction. Fig. 2A
shows that there is a dose dependent increased
35SO4 incorporation in this fraction upon treatment
with lipidated ApoE3 or ApoE4, whereas Fig. 2B
shows the time course of 35SO4 incorporation after
ApoE addition. No signi¢cant change compared to
the control was observed when using non-lipidated
ApoE (data not shown).
From the above experiments it can be concluded
that in the presence of ApoE4 higher 35SO4 incorpo-
ration was found compared with that observed after
ApoE3 addition.
The ability of ApoE4 to increase sulfate incorpo-
ration even at early time points could suggest an
increase in synthesis rather than in sulfation.
To test if increased 35SO4 incorporation was
caused by an increase of sulfation of GAG or, sim-
ilarly, by an increase in GAG synthesis, a similar
experiment as before was repeated but in this case
a double labeling with 35SO4 and 3H-glucosamine (to
label GAG) was done. Although both forms of
ApoE increased glucosamine incorporation (not
shown), Fig. 3 shows that there is a net increase in
the sulfation as noticed by the increase in the ratio
35SO4/3H with the amount of ApoE added, and
again higher 35SO4 incorporation was found for
ApoE4 compared to that of ApoE3 addition. Fur-
thermore the increase in GAG sulfation was found
after normalizing for protein. In addition, experi-
ments in which the cells were prelabeled with 35SO4
and chased for di¡erent times in the absence or pres-
ence of ApoE, it was noticed that ApoE4 altered the
turnover rates of GAGs (not shown). Taken together
these results suggest that the increased ApoE4-in-
duced sulfate incorporation is not due in great part
to increased synthesis.
The results shown in the present work indicate
that in the presence of ApoE4 there is an increase
in the level of sulfation of GAG of neuroblastoma
cells, being a level higher than found upon the addi-
tion of ApoE3.
This e¡ect, for the whole ApoE, was observed to
be similar in endothelial cells but not in other types
[12]. However, the increase in sulfation of GAG
found in neuroblastoma cells, mainly for ApoE4
could have an important implication in some neural
disorders, like AD, if it also occurs in other neural
cells. In AD, NFT containing tau protein aggregates
and sGAG can be found [4] and it has been shown
that sulfated, but not unsulfated, glycosaminoglycans
could facilitate tau aggregation into polymers resem-
bling the PHF found in AD [6,7]. On the other hand,
ApoE4 is a risk factor in sporadic AD [8]. Thus, the
Fig. 3. ApoE produces a net increase in the sulfation of GAGs.
Con£uent monolayers of neuroblastoma cells in 100 mm plates
were incubated with the indicated amounts of the recombinant
isoform ApoE3 or ApoE4 for 16 h in growth medium (DMEM
and 15% fetal calf serum) containing [35S]sulfate (250 WCi/plate)
and [3H]glucosamine (250 WCi/plate) at 37‡C, 95% CO2 and 5%
O2. Labeled cell-associated and extracellular GAGs were ex-
tracted and determined. The ratio of 35S to 3H was calculated
from these data.
BBADIS 60080 15-3-01
P. Bonay, J. Avila / Biochimica et Biophysica Acta 1535 (2001) 217^220 219
presence of ApoE4 could increase sulfation of GAG
and if these sGAG are in the cytoplasm, in free form,
they could interact with tau protein facilitating its
aberrant aggregation, like that found in AD.
The main criticism for the previous model is
whether there are free glycans in the cytoplasm.
This criticism could be similar to that of the possible
interaction of free ApoE with tau protein. In that
case it was suggested that ApoE might escape intra-
cellular endosomes and enter the cytoplasm by an
unknown mechanism [9]. However, this possibility
remains under discussion. It is not known if a similar
feature could occur for sGAG. However, in the case
of oligosaccharides (OS), mainly of polymannose
type OS, a release of free OS into the cytosol has
been shown [18]. It is not known if that process
could occur for other glycans, but if this is the
case, the previous model could be feasible. Alterna-
tively, the possible interaction of tau with sGAG in
another cell compartment cannot be excluded [19].
In summary, the increased level of sulfation of
GAG induced by ApoE4 could explain, in part,
that such an allele of apoE could act as a risk factor
in sporadic AD, since it could have a role in promot-
ing the aberrant aggregation of tau protein.
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